← 返回前沿论文

透明细胞肾细胞癌中关键免疫细胞功能改变的预后意义

英文原题:Prognostic significance of key immune cell functional alterations in clear cell renal cell carcinoma.

PubMed 2025/10/28(内容时间) Transl Cancer Res Q3 · IF 2.1(JCR 2025)

研究概要

在ccRCC中,CD8+ T细胞和NK细胞展现出功能极化及改变的细胞通讯,表明抗肿瘤免疫增强。免疫细胞来源的10基因特征提供了一个可靠的预后工具,并指导个性化治疗。

研究思路结论见上方概要

尽管免疫细胞在透明细胞肾细胞癌(ccRCC)中至关重要,但特定亚群的功能改变及其预后意义仍不清楚。我们旨在通过整合单细胞RNA测序(scRNA-seq)和批量RNA测序(RNA-seq)数据,识别关键免疫细胞,描述其功能状态,并构建预后模型。

分析scRNA-seq数据集GSE210038以注释肿瘤浸润免疫细胞。使用支持向量机-递归特征消除(SVM-RFE)、最小绝对收缩和选择算子(LASSO)和随机森林(RF)算法,从去卷积的癌症基因组图谱-肾透明细胞癌(TCGA-KIRC)和基因表达综合系列(GSE)105261数据集中鉴定关键免疫细胞。免疫反应富集分析(IREA)描绘了关键免疫细胞响应细胞因子的极化状态。通过CellChat分析细胞通讯。通过单因素Cox和LASSO回归筛选与关键免疫细胞相关的预后基因。构建风险评分(RS)模型并在TCGA-KIRC(训练,n=511)和E-MTAB-1980(验证,n=101)队列中进行验证。受试者工作特征(ROC)曲线评估总生存期(OS)预测效能。进行列线图和药物敏感性分析。

七种免疫细胞类型浸润ccRCC。CD8 + T细胞和自然杀伤(NK)细胞被确定为关键免疫细胞。IREA揭示了CD8 + T细胞中的T8-c极化[富集干扰素(IFN)-α1/白细胞介素(IL)-36α]和NK细胞中的NK-f极化(富集IL-18/IL-2)。CellChat分析显示,从关键免疫细胞到癌症相关成纤维细胞的蛋白酶激活受体(PARs)信号增强,但到巨噬细胞的膜联蛋白A1(ANXA1)-甲酰肽受体1(FPR1)信号减弱。十个免疫细胞相关预后基因(PTTG1、CLEC2D、PLIN2、LRBA、ABCB1、MIR155HG、ADAM8、P2RY8、SORL1、CD82)被用于构建RS模型。该模型将患者分为高/低风险组,具有不同的OS(log-rank P<0.001)。1年/3年/5年OS的曲线下面积(AUC)分别为0.751/0.734/0.747(训练集)和0.742/0.740/0.778(验证集)。列线图[结合RS和转移分期(M分期)]显示出稳健的校准。药物敏感性分析显示,低风险患者对酪氨酸激酶抑制剂反应更好,而高风险患者对B细胞淋巴瘤-2抑制剂敏感。

展开英文摘要原文

BACKGROUND: While immune cells are pivotal in clear cell renal cell carcinoma (ccRCC), functional alterations of specific subsets and their prognostic implications remain unclear. We aimed to identify key immune cells, characterize their functional states, and develop a prognostic model by integrating single-cell RNA sequencing (scRNA-seq) and bulk RNA sequencing (RNA-seq) data. METHODS: scRNA-seq dataset GSE210038 was analyzed to annotate tumor-infiltrating immune cells. Key immune cells were identified from deconvolved The Cancer Genome Atlas-Kidney Renal Clear Cell Carcinoma (TCGA-KIRC) and Gene Expression Omnibus Series (GSE)105261 datasets using support vector machine-recursive feature elimination (SVM-RFE), least absolute shrinkage and selection operator (LASSO), and random forest (RF) algorithms. Immune Response Enrichment Analysis (IREA) delineated polarization states of key immune cells in response to cytokines. Cellular communication was profiled via CellChat. Prognostic genes associated with key immune cells were screened by univariate Cox and LASSO regression. A risk score (RS) model was constructed and validated in TCGA-KIRC (training, n=511) and E-MTAB-1980 (validation, n=101) cohorts. Receiver operating characteristic (ROC) curves evaluated overall survival (OS) prediction efficacy. Nomograms and drug sensitivity analyses were performed. RESULTS: Seven immune cell types infiltrated ccRCC. CD8 + T and natural killer (NK) cells were identified as the key immune cells. IREA revealed T8-c polarization in CD8 + T cells [enriched for interferon (IFN)-α1/interleukin (IL)-36α] and NK-f polarization in NK cells (enriched for IL-18/IL-2). CellChat analysis showed amplified protease activated receptors (PARs) signaling from key immune cells to cancer-associated fibroblasts, but attenuated Annexin A1 (ANXA1)-formyl peptide receptor 1 (FPR1) signaling to macrophages. Ten immune-cell-associated prognostic genes ( PTTG1, CLEC2D, PLIN2, LRBA, ABCB1, MIR155HG, ADAM8, P2RY8, SORL1, CD82 ) were used to build the RS model. The model stratified patients into high/low-risk groups with distinct OS (log-rank P<0.001). The area under the curves (AUCs) for 1-/3-/5-year OS were 0.751/0.734/0.747 (training) and 0.742/0.740/0.778 (validation). The nomogram [incorporating RS and metastatic stage (M stage)] showed robust calibration. Drug sensitivity analysis revealed low-risk patients responded better to tyrosine kinase inhibitors, while high-risk patients were sensitive to a B-cell lymphoma-2 inhibitor. CONCLUSIONS: CD8+ T and NK cells exhibit functional polarization and altered cellular communication indicative of augmented anti-tumor immunity in ccRCC. The immune-cell-derived 10-gene signature provides a reliable prognostic tool and guides personalized therapy.

论文信息

作者
Wu Y、Zhang Y、Sun K、Niu W、Mei Y、Zhu S、Quan C
单位
Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China.China
期刊
Translational cancer research2025 Oct 31
原文标识
PubMed 41234823 · DOI 10.21037/tcr-2025-971